surface, said topical formulation comprises:

(1) about 1-30% (w/w) oil;

(2) about 1-5% (w/w) emulsifying agent ;

(3) about 1-15% (w/w) permeation enhancer;

(4) about 0.001-2% (w/w) preservative;

(5) about 65-90% (w/w) aqueous phase; and

(6) about 0.01-10% (w/w) cosmetic or pharmaceutical active ingredient.

31. The formulation of claim 30, wherein said topical formulation comprises:

(1) about 10-20% (w/w) oil;

(2) about 3% (w/w) emulsifying agent;

(3) about 10% (w/w) permeation enhancer;

(4) about 0.01-1% (w/w) preservative;

(5) about 82% (w/w) aqueous phase; and

(6) about 0.05-5%, (w/w) cosmetic or pharmaceutical active ingredient.

32. The formulation of claim 31, wherein said topical formulation comprises:

(1) about 0.1-0.5%, (w/w) preservative; and

(2) about 0.1-1%, (w/w) cosmetic or pharmaceutical active ingredient.

33. The topical formulation of claim 30, which is an oil-in-water formulation, a cream, a lotion, a gel, or a gel-cream.

34. The topical formulation of claim 30, wherein the mucosal surface is mucosa in the mouth, vaginal mucosal surface, mucosa of the eye.

35. The topical formulation of any one of claims 30-34, wherein the active ingredient is: Compound 1, Compound 2; or wherein the active ingredient is effective to treat psoriasis, plaque psoriasis, nail psoriasis, psoriatic arthritis, hidradenitis suppurativa, alopecia areata / universalis, vitiligo, AKT keratosis (age spots), itch, or atopic dermatitis.

36. The topical formulation of claim 35, wherein the active ingredient is Compound 1.

37. The topical formulation of claim 35, wherein the active ingredient is Compound 2.

38. Use of a topical formulation of claim 30, in the manufacture of a medicament for treating a skin or mucosal surface lesion.

39. The use of claim 38, wherein the lesion is caused by psoriasis, plaque psoriasis,